Journals / Turkish Journal of Medical Sciences / 2014 / Cilt: 44 - Sayı: 1

Bone mineral density and vitamin D status in children and adolescents with congenital adrenal hyperplasia

Pages
109–114
Publication Date
2014-05-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

A serum 25-hydroxyvitamin D level of

📌 3 Key Takeaways

🎯
Objective & Hypothesis:To determine the prevalence of and risk factors for decreased bone mineral density (BMD) and vitamin D deficiency in children and adolescents with congenital adrenal hyperplasia (CAH).
📊
Key Findings & Data:Materials and methods: This study was conducted on 30 girls and 22 boys with CAH (age range = 5-20 years) with median age of 12.0 years.
💡
Conclusion & Impact:A serum 25-hydroxyvitamin D level of
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Key words: Congenital adrenal hyperplasia · bone mineral density · adolescent

Abstract

To determine the prevalence of and risk factors for decreased bone mineral density (BMD) and vitamin D deficiency in children and adolescents with congenital adrenal hyperplasia (CAH). Materials and methods: This study was conducted on 30 girls and 22 boys with CAH (age range = 5-20 years) with median age of 12.0 years. BMD values of lumbar vertebras (L1-L4), which were determined by dual-energy X-ray absorptiometry, were used to calculate z-scores according to chronological age. A serum 25-hydroxyvitamin D level of

Özet

To determine the prevalence of and risk factors for decreased bone mineral density (BMD) and vitamin D deficiency in children and adolescents with congenital adrenal hyperplasia (CAH). Materials and methods: This study was conducted on 30 girls and 22 boys with CAH (age range = 5-20 years) with median age of 12.0 years. BMD values of lumbar vertebras (L1-L4), which were determined by dual-energy X-ray absorptiometry, were used to calculate z-scores according to chronological age. A serum 25-hydroxyvitamin D level of

🔖

Cite This Article

DEMİREL, F., KARA, Ö., TEPE, D., ESEN, İ. (2014). Bone mineral density and vitamin D status in children and adolescents with congenital adrenal hyperplasia. Turkish Journal of Medical Sciences, Cilt: 44 - Sayı: 1, 109–114. https://ajindex.com/articles/394098

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Miller WL, Acherman JC, Flück CE. The adrenal cortex and its disorder. In: Sperling MA, editor. Pediatric Endocrinology. 3rd ed. Philadelphia, PA, USA: Saunders Elsevier; 2008. pp. 444–511.
  2. Nimkarn S, Lin-Su K, New MI. Steroid 21 hydroxylase deficiency congenital adrenal hyperplasia. Pediatr Clin North Am 2011; 58: 1281–1300.
  3. Reisch N, Arlt W, Krone N. Health problems in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Horm Res Paediatr 2011; 76: 73–85. Leonard MB. Glucocorticoid-induced osteoporosis in children: impact of the underlying disease. Pediatr 2007; 119: 166–174. Kim HJ. New understanding of glucocorticoid action in bone cells. BMB Rep 2010; 43: 524–529.
  4. Falhammar H, Filipsson H, Holmdahl G, Janson PO, Nordenskjöld A, Hagenfeldt K, Thorén M. Fractures and bone mineral density in adult women with 21-hydroxylase deficiency. J Clin Endocrinol Metab 2007; 92: 4643–4649.
  5. Sciannamblo M, Russo G, Cuccato D, Chiumello G, Mora S. Reduced bone mineral density and increased bone metabolism rate in young adult patients with 21-hydroxylase deficiency. J Clin Endocrinol Metab 2006; 91: 4453–4458.
  6. King JA, Wisniewski AB, Bankowski BJ, Carson KA, Zacur HA, Migeon CJ. Long-term corticosteroid replacement and bone mineral density in adult women with classical congenital adrenal hyperplasia. J Clin Endocrinol Metab 2006; 91: 865– 8 Bachelot A, Plu-Bureau G, Thibaud E, Laborde K, Pinto G, Samara D, Nihoul-Fékété C, Kuttenn F, Polak M, Touraine P. Long-term outcome of patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Horm Res 2007; 67: 268–276.
  7. Cetinkaya S, Kara C. The effect of glucocorticoid replacement therapy on bone mineral density in children with congenital adrenal hyperplasia. J Pediatr Endocrinol Metab 2011; 24: 265–269.
  8. Abd El Dayem SM, Anwar GM, Salama H, Kamel AF, Emara N. Bone mineral density, bone turnover markers, lean mass, and fat mass in Egyptian children with congenital adrenal hyperplasia. Arch Med Sci 2010; 6: 104–110.
  9. Sahakitrungruang T, Wacharasindhu S, Supornsilchai V, Srivuthana S, Kingpetch K. Bone mineral density and body composition in prepubertal and adolescent patients with the classical form of 21-hydroxylase deficiency. J Med Assoc Thai 2008; 91: 705–710.
  10. Fleischman A, Ringelheim J, Feldman HA, Gordon CM. Bone mineral status in children with congenital adrenal hyperplasia. J Pediatr Endocrinol Metab 2007; 20: 227–235.
  11. Girgis R, Winter JS. The effects of glucocorticoid replacement therapy on